Table 5

Predicted cumulative incidence of complications associated with 534 and 729 A1c Months in the DCCT-eligible subgroup of the EDC cohort compared with the reported cumulative incidence in the DCCT/EDIC intensive and conventional treatment groups at 20 years’ diabetes duration

DCCT treatment group
Conventional (n = 730)Intensive (n = 711)RRR (95% CI)
A1c Months729534
Proliferative retinopathy
 EDC predicted, based on A1c Months20.5%10.7%48% (32, 59)
 DCCT/EDIC reported, 20 years18%7%61% (47, 71)
Overt nephropathy
 EDC predicted, based on A1c Months6.1%2.8%54% (24, 73)
 DCCT/EDIC reported, 20 years12%4%67% (51, 78)
CVD
 EDC predicted, based on A1c Months8.2%4.8%41% (13, 61)
 DCCT/EDIC reported, 20 years5%3%40% (0, 65)